Provider review
HumeCare+ Review: Its Best Number Is Its Own
HumeCare+ sells compounded semaglutide at $199 a month and tirzepatide at $299, with the drug, your consultations and shipping all included — a genuinely good structure. What it also sells is a claim that its patients lose 21.5% of their body weight on average, which is more than the semaglutide trial found, more than the tirzepatide trial found, and comes from an in-house analysis nobody outside the company has seen.
A well-built program wrapped around one number it cannot support — a 21.5% average that beats both GLP-1 trials and exists only inside the company.
Worth trusting if
- You want one monthly price covering the drug, the doctor and delivery, with no membership fee on top
- You would actually use monthly body scans to see whether you are losing fat or muscle
- You want a company that names the medical group prescribing for you
Be skeptical if
- You are signing up because of the 21.5%, which no trial supports and no outsider has checked
- You are counting on the money-back promise, which the terms narrow to almost nothing
- You want to know which pharmacy makes your medication
- You live in Alabama, Arkansas, Louisiana or Mississippi
Compounded only
Phase 3 trials
Not named
None found
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Opens humecare.com. A link is not a recommendation to take anything.
Provenance
What HumeCare+ actually dispenses
Regulatory category is the axis consumers are most reliably misled about, so it comes first. Every product below is sorted by what it legally is, not by what it costs.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Semaglutide injections — $199 a month, covering the medication, provider consultations, shipping and support with no separate membership fee, and checkout says "cancel anytime". The figure is published nowhere on the site — it appears only after the intake quiz, beside a struck-through $299 nobody is shown to pay.
- Tirzepatide + Vitamin B12 + Glycine — $299 a month, a hundred more than semaglutide, with the B12 and glycine bundled at no stated extra charge. Shown against a struck-through $399, beside a claim that 17,353 people chose it today — a figure hardcoded into the page that never changes.
- Oral Semaglutide — $199 a month, the same as the weekly injection.
Evidence
Has the molecule been tested for what it is sold for?
One row per product, graded on how far the published human evidence goes for the MOLECULE inside it, for the use it is sold for — not for the molecule in general, and never a claim about this seller. Nobody trials a compounded preparation; what a trial can tell you is whether the molecule has been tested for the thing it is being advertised to do. A molecule with phase 3 evidence for one outcome has none for another, and that distinction is where peptide marketing lives.
3
Molecules with human evidence
For the use they are sold for, out of 3 products reviewed here. The evidence belongs to the molecule, not to HumeCare+.
3
Registry records cited
Each read live from ClinicalTrials.gov, never from memory. None of them tested this company's product.
The comparison
What they claim, against what the trials show
Each claim below is quoted verbatim from HumeCare+’s own page, with the page it came from. Grading a paraphrase would prove nothing. Every row is the verdict at a glance — tap it to open the quote, the trial registry entries, and the full note behind that verdict.
Semaglutide injectionsSemaglutide · Compounded (503A)Claim reaches past the trials
“Lose up to 21.5% body weight […] HumeCare+ patients lose on average: 21.5% body weight in 10 months. Based on an internal analysis of 10 month results from 6,846 HumeCare+ members. *Individual results may vary”
Read on the HumeCare+ site, August 2026
Phase 3 trials
What the trials show for Semaglutide
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. Semaglutide 2.4 mg over 68 weeks — roughly 14.9% mean weight loss from baseline against 2.4% on placebo, with lifestyle intervention in both arms.
Semaglutide has real phase 3 weight-loss evidence, and the problem is not the molecule — it is the size of the number Hume puts on it. STEP 1 produced about 14.9% mean weight loss over 68 weeks under trial conditions. 1 Hume claims its members average 21.5% in ten months, which is both a larger result and a faster one, from a real-world population that trials consistently underperform rather than beat. The source is "an internal analysis of 10 month results from 6,846 HumeCare+ members" — not a trial, not published, not peer-reviewed, with methodology offered only "on request". The same 21.5% also appears in the hero as "Lose up to 21.5% body weight", so one figure is presented as a ceiling in one place and an average in another, and those cannot both be true.1
Tirzepatide + Vitamin B12 + GlycineTirzepatide · Compounded (503A)Claim reaches past the trials
“Dual-action: Targets two appetite hormones. Max potency: Stronger appetite suppression and weight loss. Glycine: Enhances sleep, muscle protection, and recovery. Vitamins B6 & B12: Combat nausea, fatigue, and energy loss. […] Glycine, B12, and B6 protect muscle and ease side effects, built in.”
Read on the HumeCare+ site, August 2026
Phase 3 trials
What the trials show for Tirzepatide
- NCT04184622 SURMOUNT-1 — Phase 3, completed, n=2,539. Tirzepatide over 72 weeks; roughly 20-22% mean weight reduction at the highest tolerated dose, with lifestyle intervention in every arm.
As of 2026-08-14 the site publishes no trial, no dose and no citation for its glycine, B6 or B12 additions, and no study of the blended preparation it actually sells. Its only lean-mass source is its own internal analysis. This records what the site publishes; it is not a claim that no such literature exists.
Tirzepatide's own phase 3 data is strong — about 20-22% mean weight reduction over 72 weeks at the highest tolerated dose. 2 The site-wide claim of 21.5% average at ten months still reaches past it, on a shorter clock and from an in-house analysis rather than a trial. The bigger gap here is the blend. This product is sold as tirzepatide plus glycine, B6 and B12, with the site stating those additions "protect muscle and ease side effects" — and attaching no dose, no trial and no citation to any of it. The trial above tested tirzepatide, not this combination. The "HOW WE COMPARE" table goes further still, scoring unnamed "Standard GLP-1 Programs" at "50% Loss common" for muscle against "80% More Preserved" here, and claiming this program reverses metabolic age while others age you. Those rows carry no source at all.2
Oral SemaglutideSemaglutide · Compounded (503A)No trial supports this claim
“The oral pill contains semaglutide, a clinically-proven ingredient. A once-daily oral GLP-1 medication for weight management. Helps regulate appetite and blood sugar. Slows digestion to keep you feeling full longer. Formulated for increased absorption in pill form.”
Read on the HumeCare+ site, August 2026
Phase 3 trials
What the trials show for Semaglutide
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. The phase 3 weight-loss evidence for semaglutide is for the once-weekly SUBCUTANEOUS 2.4 mg dose. It is not evidence for a compounded oral preparation at an unstated dose.
As of 2026-08-14 the site publishes no dose, no strength and no bioavailability figure for its oral semaglutide, and names no study of the oral preparation it sells. The phrase it uses instead is that the pill is 'Formulated for increased absorption in pill form'.
"The oral pill contains semaglutide, a clinically-proven ingredient" is the claim, and it does the work of transferring an injection's evidence to a pill. The phase 3 weight-loss data for semaglutide is for a once-weekly subcutaneous injection. 1 The approved oral semaglutide product is a specific tablet built around an absorption enhancer, and a compounded oral preparation is neither of those things. Hume states no dose, no strength and no bioavailability for what it is actually selling — only that it is "formulated for increased absorption in pill form", which is a description of an intention rather than a measurement. It also costs the same $199 a month as the injection, so there is no saving to offset the weaker evidence.1
Dispensing chain
Who actually fills your prescription
Read the full account
No compounding pharmacy is named anywhere on the site or in the terms, which describe only "licensed compounding pharmacies". A reader cannot look up a license number, because no licensee is identified. What Hume does name is the clinical side: it states that it provides no clinical services itself and that all prescribing is done by an independent network, and its terms link that network's own patient agreement at mdintegrations.com — so the prescribing group is MD Integrations, and it is identified. That is more than most companies here disclose. The company never states whether its pharmacies are 503A or 503B; the terms describe patient-specific prescriptions, which is the 503A pathway, and that classification is our reading rather than its statement.
Read on the HumeCare+ site, August 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Nothing published on the pages searched
Certificate of analysis readable
No lot report a buyer can open
Read the full testing account
No certificate of analysis is published, offered on request, or mentioned. The quality signals on offer are accreditation badges on a product photograph — a Pharmacy Compounding Accreditation Board mark, an American Board of Obesity Medicine mark and a LegitScript certification mark — none of which is a test result for the medication you receive, and none of which names the pharmacy they belong to. What the terms do get right is the regulatory status: they state in capitals that compounded medications are not FDA-approved, have not been reviewed by the FDA for safety, efficacy or manufacturing quality, and are not interchangeable with the branded drugs. That is the clearest version of that disclosure we have seen in this market.
Read on the HumeCare+ site, August 2026.
Licensing
Licensed to dispense, and where
Coverage
HumeCare+ publishes a dated coverage page listing every state it serves by region, and an explicit "Unavailable" section naming Alabama, Arkansas, Louisiana and Mississippi. Counted from that list, it treats 46 states plus Washington, D.C. It is one of the few companies here that names where it cannot help you instead of leaving you to discover it at checkout.
Read the full licensing claim
Availability may change based on regulations and clinician licensing
Named as outside that footprint
Read on the HumeCare+ site, August 2026.
Regulatory
The FDA warning letter
Checked, and none found
We did this ourselves
What happens when you sign up with HumeCare+
We went through HumeCare+’s signup ourselves in August 2026 to find out what you actually meet before you pay — the steps, when a price appears, and what it asks for. We used placeholder answers, and we stopped before paying, so nothing here is a prescription or a medical outcome. It is what the screens showed.
- Start the free assessment from the homepage. No price is published anywhere on it.
- Answer roughly two dozen screens: goal, gender, target weight, name, height, weight, date of birth, timeline and whether you have taken a GLP-1 before.
- Give an email address partway through to unlock the weight prediction the questions have been building.
- Work through the medical screening — bariatric surgery, thyroid and pancreatic history, current medications — then pick your state.
- Read about ten marketing screens threaded between the questions, each one ending in a button rather than a question.
- Choose a medication type and a priority, then wait on a screen that says it is preparing your treatment match.
- The prices arrive on the last screen, three of them, under a countdown clock.
- $199 a month buys the semaglutide injection, $299 the tirzepatide with B12 and glycine, and $199 the oral semaglutide. Each is shown against a struck-through figure exactly a hundred dollars higher that nobody is shown paying.
- One number covers the medication and prescription, the provider consultation, shipping and 24/7 clinical support, with “Cancel anytime” printed beside it.
- The offer sits under a clock that started at nine minutes and twenty-three seconds, on a page reached only after every question is answered.
- The price screen claims up to 22.5% body weight for the weekly injection and up to 17% for the daily pill. The homepage advertises a 21.5% average. Three numbers, no source for any of them.
- Each plan carries a counter saying how many people chose it today: 17,353 for tirzepatide, 1,985 for semaglutide, 1,048 for the oral. The tirzepatide figure was identical when we read the same page on 14 August.
- No lab work and no video visit were demanded at any point before the price.
- The FDA disclosure sits directly under the price — compounded medications not evaluated for safety, quality or efficacy, plus the thyroid C-cell tumor warning.
HumeCare+ support
- support@humecare.com
Assessment
What holds up, and what does not
- Its terms state in capitals that compounded medications are not FDA-approved and not interchangeable with the branded drugs.
- It names the group that actually prescribes for you, MD Integrations, which most companies here refuse to do.
- One price covers everything: $199 a month includes the medication, consultations, shipping and support with no membership fee.
Show 4 more
- It publishes a dated state-by-state coverage page that names the four states it cannot treat.
- It is upfront that it does not bill insurance, Medicare or Medicaid.
- Checkout says “cancel anytime” under the price, and repeats the thyroid tumor risk and the FDA's non-evaluation at the point of sale.
- Measuring fat and muscle separately is a real improvement on a bathroom scale, whatever the marketing around it claims.
- It claims patients lose 21.5% of their body weight on average — more than either the semaglutide or tirzepatide trial achieved, and in less time.
- That figure comes from its own unpublished analysis, with the methodology available only on request.
- The same 21.5% is presented as a maximum in one place on the page and an average in another.
Show 8 more
- Its comparison table claims 80% better muscle preservation and reversed metabolic age against unnamed rival programs, with no source for either.
- The glycine and B12 added to the tirzepatide are sold as muscle protection with no dose, no trial and no citation attached.
- The oral pill borrows the injection's evidence while publishing no dose, no strength and no absorption figure of its own.
- The same customer testimonials carry different weight-loss figures on different pages of the site.
- The “chosen today” counts beside each plan are fixed numbers written into the page — they count nothing and never change.
- Those counts total 20,386 people choosing a plan in one day, at a company that claims 20,000+ customers in total.
- The front page promises your money back if you do not lose 10% in six months; the terms refund you only if you lose nothing at all in 90 days.
- No pharmacy is named, so there is no license you can look up and no certificate of analysis to ask for.
Verdict
The bottom line
On structure this is one of the better programs here: $199 a month all-in, the prescribing group named, the compounding disclosure written properly, and a coverage page that admits where it cannot help. On evidence it is one of the weaker ones, because the claim doing the selling — 21.5% average weight loss in ten months — is bigger than either registrational trial and exists only inside the company. Buy it for the structure if you want it. Do not buy it for the number.
Opens humecare.com. A link is not a recommendation to take anything.
The number that does not fit
The first thing HumeCare+ tells you is that you could "lose up to 21.5% body weight". Scroll down and the same figure reappears, but changed:
"HumeCare+ patients lose on average: 21.5% body weight in 10 months. Based on an internal analysis of 10 month results from 6,846 HumeCare+ members."
A maximum in one place, an average in the other. Those are very different promises and they cannot both describe the same number.
Take the second one at face value, because it is the stronger claim. An average of 21.5% in ten months would be better than either drug managed in the trials that got them approved.
Semaglutide's big weight-loss trial averaged about 14.9% over 68 weeks. 1 Tirzepatide's averaged about 20-22% over 72 weeks, at the highest dose people could tolerate. 2 Both were run under trial conditions, with lifestyle support built into every arm, and with the follow-up that trials pay for and real clinics do not.
HumeCare+ says its members beat both, faster.
That is not impossible. It is just a claim that would be significant if true, and the only thing standing behind it is an in-house analysis that has not been published, has not been reviewed by anyone outside the company, and whose methodology is available "on request".
Worth noting: Hume links the semaglutide trial itself, as reference 2 in its own footer. It is exceeding a result it cites.
Full analysis — 7 more sectionsThe other numbers do not agree either · The comparison table · Muscle, glycine and B12 · The pill that borrows the injection's evidence · The money-back promise has two versions · What it gets right · What this means if you are buying
The other numbers do not agree either
Once you start counting, the supporting figures drift.
The 21.5% is based on 6,846 members. A separate internal study in the footer describes 8,000 premium members. The homepage says the company is trusted by 20,000+ Americans. Two screens into the sign-up quiz, it says it has helped over 23,323 members.
The testimonials move too. On the homepage, Arthur lost 112.4 lbs in 12 months and Jenny lost 90.4 lbs in 9. Inside the quiz, Arthur lost 95.2 lbs in 12 months and Jenny lost 125.5 lbs in 8 — while Jenny's original 90.4 lbs has been reassigned to a man named Miguel.
And at checkout, each plan carries a live-looking counter: 17,353 chosen today for tirzepatide, 1,985 for the semaglutide injection, 1,048 for the pill.
Those are not counts. They are fixed numbers written into the page's code, with nothing that could update them — no clock, no lookup, no randomness. They will read the same tomorrow.
They also add up to 20,386 people choosing a plan today, at a company whose own homepage says it is trusted by 20,000+ Americans in total.
None of this proves anyone is lying. All of it means the numbers on this site are not being handled as if they were facts.
The comparison table
Under "HOW WE COMPARE", HumeCare+ scores itself against "Standard GLP-1 Programs": 60% higher fat loss, 80% more muscle preserved, and a metabolic age that "Reverses (Youth)" here while it "Increases (Aging)" everywhere else.
There is no source on any of those rows, no definition of what a standard program is, and no study named. It is the most quantitative-looking block on the page and the least supported.
Muscle, glycine and B12
The tirzepatide plan is sold as tirzepatide plus glycine, B6 and B12, and the pitch is that those additions "protect muscle and ease side effects, built in."
Muscle loss on GLP-1s is a real concern and a reasonable thing to build a product around. But the trial evidence above is for tirzepatide on its own. Hume attaches no dose, no trial and no citation to the glycine or the vitamins, and the only lean-mass evidence it offers is, once again, its own internal analysis.
So the idea is sound and the product may well be fine. The claim that it protects your muscle is simply not shown.
The pill that borrows the injection's evidence
The oral option is described as containing "semaglutide, a clinically-proven ingredient".
That sentence is doing a lot of work. The weight-loss evidence for semaglutide is for a once-weekly injection under the skin. 1 The approved oral version of semaglutide is a specific tablet engineered around an absorption enhancer — a genuinely difficult piece of pharmaceutics, because semaglutide is poorly absorbed by mouth.
A compounded oral preparation is neither of those. And HumeCare+ publishes no dose, no strength and no absorption figure for the one it sells, saying only that it is "formulated for increased absorption in pill form."
It also costs exactly the same as the injection, so you take the weaker evidence and save nothing.
The money-back promise has two versions
The homepage version:
"Lose 10% body weight or get your money back. We're confident that you'll lose at least 10% of your body weight in 6 months. If you don't, we'll refund you."
The version in the terms is a 90-day guarantee, and it pays out only if you "do not achieve any measurable weight loss" at all. Lose two pounds and you no longer qualify.
It also requires that you have never taken a GLP-1 before, that you take and log every dose with none missed, that you complete all thirteen weekly weigh-ins on their scale, that you follow every piece of clinical advice, and that you are still paying at the end. You then have 14 days to claim, and the consultation fee is never refunded.
One promise refunds you for falling short of a target. The other refunds you only for total failure. They are on the same website.
What it gets right
More than the tone of this review might suggest.
The compounding disclosure in its terms is the clearest we have seen in this market — capitals, no hedging: not FDA-approved, not reviewed for safety, efficacy or manufacturing quality, not interchangeable with the branded drugs. Plenty of companies here invent an FDA category that does not exist. This one does the opposite.
It names MD Integrations as the prescribing network, when most sites here will not tell you who writes your prescription. It publishes a dated coverage page that names the four states it cannot serve. It says plainly that it does not bill insurance. And the price genuinely is all-in — medication, consultations, shipping and support in one monthly figure, with no membership fee bolted on underneath, sold with "cancel anytime" printed under it rather than a minimum term.
The checkout page is the best-behaved surface on the site. It repeats that compounding pharmacies are licensed by Boards of Pharmacy and that the FDA has not evaluated these medications for safety, quality or efficacy, and it names the thyroid C-cell tumor and medullary thyroid carcinoma risk — at the moment of payment, where it is least convenient and most useful.
What it will not tell you is which pharmacy makes the drug, or what a vial contains.
What this means if you are buying
If the structure appeals — one bill, named prescribers, body scans that separate fat from muscle — this is a reasonable program at a reasonable price, and better disclosed than much of the market on the things that are hardest to disclose.
Just separate that from the number on the front page. The 21.5% is the company's own, it is bigger than what either drug achieved in trials, and nobody outside HumeCare+ has seen the working.
Questions
Frequently asked questions
Do HumeCare+ patients really lose 21.5% of their body weight?
That is the company's own figure from its own unpublished analysis of 6,846 members, and it is larger than either drug managed in trials. Semaglutide averaged about 15% over 68 weeks and tirzepatide about 21% over 72 weeks, both under trial conditions. A real-world program averaging more than that, in ten months, is a claim no independent source supports.
What does HumeCare+ cost?
Compounded semaglutide is $199 a month whether you take the weekly injection or the daily pill, and tirzepatide is $299. That covers the medication, your consultations, shipping and support, so there is no separate membership fee — but you won't see a price until you have completed the health quiz.
Is the money-back guarantee worth anything?
Much less than the homepage implies. The front page offers a refund if you do not lose 10% of your body weight in six months; the terms offer one only if you achieve no measurable weight loss at all in 90 days. You must also be new to GLP-1s, miss no doses, complete all 13 weigh-ins and still be paying at the end.
Does the glycine and B12 protect muscle?
HumeCare+ says so, and does not show it. The tirzepatide plan bundles glycine, B6 and B12 with the claim that they protect muscle and ease side effects, but no dose, no trial and no citation is attached to any of them, and the trial evidence for tirzepatide is for the drug alone.
Is the oral pill as good as the injection?
There is no published evidence that it is, and it costs the same. The phase 3 weight-loss data for semaglutide is for a weekly injection under the skin, the approved oral product is a specially engineered tablet, and HumeCare+ publishes no dose, strength or absorption figure for its compounded pill.
Who prescribes and who compounds the medication?
Hume states it provides no clinical care itself, and its terms identify the prescribing network as MD Integrations. It does not name the compounding pharmacy anywhere, so there is no license number to check and no certificate of analysis to request.
Where is HumeCare+ available?
In 46 states plus Washington, D.C. It cannot treat you in Alabama, Arkansas, Louisiana or Mississippi, and unusually it lists those four explicitly on a dated coverage page.
Compare
Others selling what HumeCare+ sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
Method
How we checked this
Non-product facts last checked August 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off HumeCare+'s own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 2 sources
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine 387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.